The Zacks Analyst Blog Highlights Eli Lilly, RTX, Abbott Laboratories, Ohio Valley Banc and Rave Restaurant
- 📈 Zacks Equity Research analysts published new daily reports covering major stocks including Eli Lilly, RTX, Abbott Laboratories, Ohio Valley Banc, and Rave Restaurant Group on March 24, 2026.
- 💊 Eli Lilly's shares have outperformed the large cap pharmaceuticals industry by 23.4% over six months driven by strong demand for GLP-1 drugs Mounjaro and Zepbound.
- 🚀 Lilly continues to expand its portfolio with new launches like Kisunla and Omvoh, plus an oral GLP-1 obesity pill called orforglipron expected this year.
- ⚠️ Investors face potential headwinds for Eli Lilly from declining Trulicity sales, pricing pressure on existing drugs, and emerging competition in the diabetes and obesity markets.
- 🛡️ RTX Corp. shares have outperformed the aerospace-defense industry by 22.8% due to strong defense orders from the Pentagon and allies alongside improving global commercial air traffic.
- 🔋 RTX reported a record backlog of $268 billion as of December 31, 2025, supported by steady volumes in large commercial engines and Pratt Canada operations.
- 🏭 The aerospace sector faces ongoing supply-chain challenges and risks related to recent U.S. government import tariffs that could adversely impact RTX's growth momentum.
- 🩺 Abbott Laboratories' shares have declined 15.1% over the past year, though the company maintains a strong product pipeline supporting growth into 2026.
- 🧬 Abbott's Medical Devices segment is driven by the FreeStyle Libre CGM franchise and expansion in Diabetes Care, while Diagnostics sees improving demand outside China.
- 🍽️ Abbott's Nutrition business is transitioning after near-term volume and pricing issues, with Adult Nutrition innovations expected to support growth starting in the second half of 2026.
- 🏦 Ohio Valley Banc shares have outperformed the Midwest banking industry by 15.6% due to balance-sheet optimization and a strategic shift toward higher-yielding commercial lending.
- ⚠️ The regional bank faces elevated credit sensitivity from its increased concentration in commercial assets, with early signs of asset quality pressure emerging.
- 🍕 Rave Restaurant Group shares have underperformed the restaurant industry by 28.9% due to limited net unit expansion and structural drag from its Pie Five brand.
- 💸 Rave's revenue visibility is constrained by reliance on incentive income, though the company offers a differentiated asset-light franchise model anchored by Pizza Inn's buffet strategy.
- 📉 The market currently prices limited growth potential for Rave Restaurant, leaving future upside dependent on sustained unit expansion and successful brand stabilization.
- Abbott Laboratories shares have outperformed the broader industry decline of -20.6%, dropping only -15.1% over the past year due to a strong product pipeline supporting growth into 2026.
- The company's Medical Devices segment, led by the FreeStyle Libre CGM franchise, remains a key driver for future expansion.
- Diagnostics demand is improving outside of China as Core Laboratory and Point of Care gain momentum in emerging markets.
- Abbott maintains a constructive outlook on its biosimilar strategy, which supports sustained growth in the EPD segment across emerging markets.
- The Nutrition business is positioned to support a return to growth in the second half of 2026 following current near-term volume and pricing challenges.
- RTX has outperformed the Aerospace-Defense industry with shares rising +22.8% versus -2.6%, fueled by ample orders for defense products from the Pentagon and foreign allies.
- Strong volumes and a favorable mix across commercial engines are expected to sustain growth momentum, resulting in a massive backlog of $268 billion as of Dec. 31, 2025.
- Eli Lilly has outperformed its industry with +23.4% gains over the past six months compared to +14%, driven by robust demand for GLP-1 drugs Mounjaro and Zepbound.
- New drugs like Kisunla, Omvoh, and Jaypirca are actively contributing to top-line growth alongside rapid pipeline progress in obesity with oral GLP-1 orforglipron expected to launch this year.
- Ohio Valley Banc has outperformed its industry with +15.6% gains over six months as balance-sheet optimization and a shift toward higher-yielding lending drive margin expansion.
- Operating efficiency gains and disciplined expense management at Ohio Valley Banc enhance scalability, while a stable core deposit base underpins funding needs.
- Abbott Laboratories shares have declined -15.1% over the past year, significantly lagging its industry peer group.
- The company faces near-term volume and pricing woes in its Nutrition segment as it transitions back to growth expected only by the second half of 2026.
- Macro uncertainty, tariffs, and China pressures limit Abbott's near-term visibility despite its diversified portfolio.
- Abbott is facing declining sales on Trulicity and rising pricing pressure on some drugs which acts as a headwind to top-line growth.
- Potential competition in the GLP-1 diabetes/obesity market poses a threat to Eli Lilly's top-line drivers.
- Supply-chain challenges continue to affect the aerospace sector, which may adversely impact RTX Corp.
- Uncertainties created by recent U.S. government-imposed import tariffs pose a specific risk for RTX Corp.
- Ohio Valley Banc faces credit sensitivity risks as greater concentration in commercial assets elevates vulnerability to early signs of asset quality pressure.
- Ohio Valley Banc is experiencing declining fee income and relies heavily on balance-sheet-driven earnings, highlighting evolving revenue risks.
- Rave Restaurant Group's shares have underperformed the sector by -28.9% over the past six months due to limited net unit expansion and reliance on system-wide sales.
- Pie Five remains a structural drag for Rave Restaurant with ongoing unit contraction and weak sales contributing to growth constraints.
- Rave Restaurant's revenue visibility is impacted by its reliance on incentive income which creates volatility in earnings.
